Prescribing of Low-density Lipoprotein Cholesterol-lowering Therapies and Eligibility for Use of Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibodies Early After ST-elevation Myocardial Infarction

Guidelines recommend early intensive low-density lipoprotein cholesterol (LDL-C)-lowering following ST-elevation myocardial infarction (STEMI). This real-world study aimed to determine whether patients are receiving intensive LDL-C-lowering therapies and the proportion who could be discharged from hospital on proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9-mAbs) post-STEMI.